On March 13, 2015 on the web-site of the Ministry of Healthcare of Ukraine the draft of the Regulation of the Cabinet of Ministers of Ukraine was published, which is consider to change the Regulation of the Cabinet of Ministers of Ukraine “On reference pricing for medicinal products and medical devices procured by the state and local budgets”, dated 02.07.2014 N 240, in the aspect of the declaring currency of wholesale and selling price (hereafter as the Draft of Regulation).
In particular, in the case of adoption of the Draft of Regulation the changes of wholesale and selling prices for medicinal products and medical devices of foreign manufacture will be declared in national and foreign currency, and products of domestic manufacture, same as before, in national currency. At that, the price declaring for medicinal products inclusive of arithmetic mean value is still.
The healthcare facilities and organizations, financed by the state and local budgets, may purchase medicinal products and medical devices at prices, which are not exceed the level of declared prices in national or foreign currency inclusive of duty, VAT and maximum supply / sales and trade (selling) markups.
The Draft of Regulation shall, in some measure, regulate the situation, when distributors sell medicinal products at prices, which exceed their declared level, because of excess of legislatively permitted speed of possible increasing of declared wholesale and selling price by rapid changes in exchange rate.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
